AR034985A1 - Compuesto biciclico; produccion y uso del mismo - Google Patents
Compuesto biciclico; produccion y uso del mismoInfo
- Publication number
- AR034985A1 AR034985A1 ARP020102986A ARP020102986A AR034985A1 AR 034985 A1 AR034985 A1 AR 034985A1 AR P020102986 A ARP020102986 A AR P020102986A AR P020102986 A ARP020102986 A AR P020102986A AR 034985 A1 AR034985 A1 AR 034985A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- substituted
- compound
- group
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/16—Eight-membered rings
- C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
Abstract
La presente provee un nuevo compuesto cíclico que tiene una actividad antagonista del CCR, especialmente una actividad antagonista del CCR5, y el uso del mismo. El compuesto de la presente está representado por la fórmula (1) en donde: R1 es un anillo de 5 a 6 miembros que puede estar sustituido; X1 es un enlace o similares; el anillo A es un anillo de 5 a 6 miembros que puede estar sustituido; el anillo B es un anillo de 8 a 10 miembros que puede estar sustituido; X2 es un grupo bivalente de 1 a 4 átomos; Z1 es un grupo de anillo cíclico bivalente o similares; Z2 es un enlace o similares; y R2 es un grupo amino, un grupo heterocíclico con contenido de nitrógeno que puede estar sustituido, o una sal del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001240750 | 2001-08-08 | ||
JP2002066809 | 2002-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034985A1 true AR034985A1 (es) | 2004-03-24 |
Family
ID=26620186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102986A AR034985A1 (es) | 2001-08-08 | 2002-08-07 | Compuesto biciclico; produccion y uso del mismo |
Country Status (14)
Country | Link |
---|---|
US (7) | US7371772B2 (es) |
EP (3) | EP2206702B1 (es) |
JP (4) | JP4316203B2 (es) |
AR (1) | AR034985A1 (es) |
AT (2) | ATE460406T1 (es) |
AU (1) | AU2002328092A1 (es) |
CA (2) | CA2459172C (es) |
DE (1) | DE60235632D1 (es) |
DK (2) | DK2206702T3 (es) |
ES (2) | ES2376855T3 (es) |
HK (1) | HK1142886A1 (es) |
PE (1) | PE20030329A1 (es) |
PT (2) | PT1423376E (es) |
WO (1) | WO2003014105A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2206702T3 (da) * | 2001-08-08 | 2012-02-13 | Tobira Therapeutics Inc | Bicyklisk forbindelse, fremstilling og anvendelse deraf |
WO2003076411A1 (fr) * | 2002-03-12 | 2003-09-18 | Takeda Pharmaceutical Company Limited | Procede de production d'un derive sulfoxyde actif sur le plan optique |
WO2004069834A1 (ja) * | 2003-02-07 | 2004-08-19 | Takeda Pharmaceutical Company Limited | 三環性化合物、その製造方法および用途 |
EP1593680A4 (en) * | 2003-02-07 | 2008-05-07 | Takeda Pharmaceutical | PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE |
US20060160864A1 (en) * | 2003-02-07 | 2006-07-20 | Mitsuru Shiraishi | Acrylamide derivative, process for producing the same, and use |
ES2425937T3 (es) * | 2004-03-24 | 2013-10-18 | Takeda Pharmaceutical Company Limited | Estabilizante de emulsión |
EP1728505B1 (en) * | 2004-03-24 | 2014-06-04 | Takeda Pharmaceutical Company Limited | Preparation with elevated content |
US20050260139A1 (en) * | 2004-03-30 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists |
JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
JPWO2006059716A1 (ja) * | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
US8426387B2 (en) * | 2006-03-31 | 2013-04-23 | Stephen Carper | Treatments for cancer |
WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
KR20110097770A (ko) * | 2008-10-17 | 2011-08-31 | 인베이스크 테라퓨틱, 인크. | 레닌-안지오텐신 알도스테론 시스템(raas) 관련 질병 치료용 조성물 및 방법 |
EP3133070B1 (en) | 2009-11-27 | 2019-08-14 | Genzyme Corporation | Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient |
BR112012024522A2 (pt) | 2010-04-02 | 2017-08-08 | Phivco 1 Llc | combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio |
WO2012047630A2 (en) * | 2010-09-27 | 2012-04-12 | Martin Teintze | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
SG11201607859SA (en) | 2014-03-21 | 2016-10-28 | Tobira Therapeutics Inc | Cenicriviroc for the treatment of fibrosis |
WO2015187663A1 (en) * | 2014-06-02 | 2015-12-10 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
RU2723559C2 (ru) | 2014-09-12 | 2020-06-16 | Тобира Терапьютикс, Инк. | Комбинированная терапия с применением препарата ценикривирок для лечения фиброза |
RU2725888C2 (ru) * | 2014-12-23 | 2020-07-07 | Тобира Терапьютикс, Инк. | Способ получения ценикривирока и родственных аналогов |
EP3256124B1 (en) | 2015-02-10 | 2020-12-23 | Tobira Therapeutics, Inc. | Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis |
KR101938036B1 (ko) * | 2015-04-16 | 2019-01-14 | 서울대학교산학협력단 | 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법 |
KR20190039087A (ko) * | 2016-06-21 | 2019-04-10 | 토비라 쎄라퓨틱스, 인크. | 정제된 세니크리비록 및 세니크리비록을 제조하기 위한 정제된 중간체 |
WO2018045043A1 (en) * | 2016-08-31 | 2018-03-08 | Tobira Therapeutics, Inc. | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |
CN110023286B (zh) | 2016-12-09 | 2021-06-01 | 南京明德新药研发有限公司 | 作为ccr2/ccr5受体拮抗剂的联苯化合物 |
AU2018223976B2 (en) | 2017-02-24 | 2023-08-17 | Genfit | Pharmaceutical compositions for combination therapy |
WO2019149089A1 (zh) | 2018-02-02 | 2019-08-08 | 四川科伦博泰生物医药股份有限公司 | 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途 |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
WO2019238041A1 (zh) * | 2018-06-12 | 2019-12-19 | 南京明德新药研发有限公司 | 一种丙烯酰胺类化合物的晶型及其制备方法 |
CN113412261A (zh) * | 2019-04-08 | 2021-09-17 | 四川科伦博泰生物医药股份有限公司 | 苯并咪唑化合物、其制备方法及其用途 |
EP3988098B1 (en) * | 2019-06-24 | 2024-07-24 | Wuxi Life Fountain Biotech Co., Ltd. | Heterocyclo alkyl compounds used as ccr2/ccr5 antagonists |
WO2021133811A1 (en) | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
JP7502467B2 (ja) * | 2020-05-22 | 2024-06-18 | メッドシャイン ディスカバリー インコーポレイテッド | ピリジン系誘導体及びその使用 |
CN112472678A (zh) * | 2020-11-12 | 2021-03-12 | 澳美制药厂有限公司 | 肾素那敏制剂及其制备方法 |
WO2023143112A1 (zh) * | 2022-01-26 | 2023-08-03 | 无锡瓴方生物医药科技有限公司 | 氮杂苯并八元环化合物的盐型、晶型及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62265270A (ja) | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
CA2191980A1 (en) | 1994-07-04 | 1996-01-18 | Takashi Sohda | Phosphonic acid compounds, their production and use |
RU2167649C2 (ru) | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
ATE270552T1 (de) | 1997-10-20 | 2004-07-15 | Dainippon Pharmaceutical Co | Von tetrahydropyrrolo (1,2-a) pyrazin-4-spiro-3'- pyrrolidine stabilisierte zusammenstellung |
KR20010032841A (ko) | 1997-12-19 | 2001-04-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 아닐리드 유도체를 함유하는 ccr5 길항용 약학 조성물 |
US6096780A (en) * | 1998-08-20 | 2000-08-01 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use |
CA2244097A1 (en) | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
CA2353635A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
EP1172097B1 (en) | 1999-04-12 | 2004-09-08 | Shionogi & Co., Ltd. | Process for producing medicinal composition of a basic hydrophobic medicinal compound |
JP2001026586A (ja) | 1999-05-07 | 2001-01-30 | Takeda Chem Ind Ltd | 環状化合物およびその用途 |
EP1211239A4 (en) | 1999-09-06 | 2003-08-06 | Takeda Chemical Industries Ltd | METHOD FOR PRODUCING 2,3-DIHYDROAZEPINE DERIVATIVES |
DK2206702T3 (da) * | 2001-08-08 | 2012-02-13 | Tobira Therapeutics Inc | Bicyklisk forbindelse, fremstilling og anvendelse deraf |
WO2003076411A1 (fr) | 2002-03-12 | 2003-09-18 | Takeda Pharmaceutical Company Limited | Procede de production d'un derive sulfoxyde actif sur le plan optique |
ES2425937T3 (es) * | 2004-03-24 | 2013-10-18 | Takeda Pharmaceutical Company Limited | Estabilizante de emulsión |
EP1728505B1 (en) * | 2004-03-24 | 2014-06-04 | Takeda Pharmaceutical Company Limited | Preparation with elevated content |
JPWO2006059716A1 (ja) * | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
WO2008030853A2 (en) | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
BR112012024522A2 (pt) | 2010-04-02 | 2017-08-08 | Phivco 1 Llc | combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio |
PE20140406A1 (es) | 2010-11-18 | 2014-04-16 | Univ Yale | Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana |
WO2013000922A1 (en) | 2011-06-27 | 2013-01-03 | Universite Pierre Et Marie Curie (Paris 6) | Ccr2 antagonist peptides |
BR112015028644A2 (pt) | 2013-05-15 | 2017-07-25 | Tobira Therapeutics Inc | composições de cenicriviroc e métodos de criação e uso do mesmo |
SG11201607859SA (en) | 2014-03-21 | 2016-10-28 | Tobira Therapeutics Inc | Cenicriviroc for the treatment of fibrosis |
RU2725888C2 (ru) | 2014-12-23 | 2020-07-07 | Тобира Терапьютикс, Инк. | Способ получения ценикривирока и родственных аналогов |
EP3256124B1 (en) | 2015-02-10 | 2020-12-23 | Tobira Therapeutics, Inc. | Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis |
-
2002
- 2002-08-07 DK DK10150963.6T patent/DK2206702T3/da active
- 2002-08-07 US US10/484,762 patent/US7371772B2/en not_active Expired - Lifetime
- 2002-08-07 JP JP2002229532A patent/JP4316203B2/ja not_active Expired - Lifetime
- 2002-08-07 ES ES10150963T patent/ES2376855T3/es not_active Expired - Lifetime
- 2002-08-07 CA CA2459172A patent/CA2459172C/en not_active Expired - Lifetime
- 2002-08-07 DK DK02762751.2T patent/DK1423376T3/da active
- 2002-08-07 ES ES02762751T patent/ES2339340T3/es not_active Expired - Lifetime
- 2002-08-07 EP EP10150963A patent/EP2206702B1/en not_active Expired - Lifetime
- 2002-08-07 CA CA002607992A patent/CA2607992A1/en not_active Abandoned
- 2002-08-07 WO PCT/JP2002/008043 patent/WO2003014105A1/en active Application Filing
- 2002-08-07 PT PT02762751T patent/PT1423376E/pt unknown
- 2002-08-07 EP EP07021230.3A patent/EP1889839B1/en not_active Expired - Lifetime
- 2002-08-07 PT PT10150963T patent/PT2206702E/pt unknown
- 2002-08-07 AT AT02762751T patent/ATE460406T1/de active
- 2002-08-07 PE PE2002000719A patent/PE20030329A1/es not_active Application Discontinuation
- 2002-08-07 DE DE60235632T patent/DE60235632D1/de not_active Expired - Lifetime
- 2002-08-07 AU AU2002328092A patent/AU2002328092A1/en not_active Abandoned
- 2002-08-07 EP EP02762751A patent/EP1423376B1/en not_active Expired - Lifetime
- 2002-08-07 AR ARP020102986A patent/AR034985A1/es not_active Application Discontinuation
- 2002-08-07 AT AT10150963T patent/ATE539062T1/de active
-
2006
- 2006-12-28 JP JP2006355701A patent/JP4358851B2/ja not_active Expired - Lifetime
-
2007
- 2007-10-25 US US11/978,198 patent/US8183273B2/en active Active
-
2008
- 2008-05-12 US US12/119,355 patent/US8362058B2/en not_active Expired - Lifetime
-
2009
- 2009-06-22 JP JP2009147839A patent/JP5275148B2/ja not_active Expired - Lifetime
-
2010
- 2010-09-27 HK HK10109225.6A patent/HK1142886A1/xx not_active IP Right Cessation
-
2012
- 2012-05-21 US US13/476,454 patent/US8741943B2/en not_active Expired - Lifetime
-
2013
- 2013-03-13 JP JP2013050937A patent/JP2013136629A/ja active Pending
-
2014
- 2014-04-25 US US14/261,683 patent/US10045968B2/en not_active Expired - Lifetime
-
2018
- 2018-08-08 US US16/058,303 patent/US20190038604A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/750,977 patent/US20200297700A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034985A1 (es) | Compuesto biciclico; produccion y uso del mismo | |
BRPI0014526B8 (pt) | compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo | |
TW201129553A (en) | Dipeptidyl peptidase inhibitors | |
EA200702080A1 (ru) | Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич | |
BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
ECSP045221A (es) | Sales de valsartan | |
RS51943B (en) | PIPERIDINSKI GPCR AGONIST | |
DE60132975D1 (de) | Neue substanzen und verbindungen als protease-inhibitoren | |
BR0311771A (pt) | Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv | |
ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
AR011913A1 (es) | Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos. | |
BRPI0511933B8 (pt) | derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BR0108303A (pt) | Derivados do 1h-imidazopiridina | |
DE60322877D1 (de) | Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität | |
PT1200426E (pt) | Tieno-3-il-sulfonilamino (tio) carbonil-triazolino (ti) onas substituidas | |
DE502005008057D1 (de) | Substituierte cyclopenten-verbindungen | |
GEP20084361B (en) | Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists | |
MX2009007954A (es) | Derivado de heterocicliden-n-(aril) acetamida. | |
DE60318826D1 (de) | Alkoxypyridinderivate | |
AR055420A1 (es) | Derivados de pirimidina sustituidos | |
FR2818906B1 (fr) | Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine | |
GT200300183A (es) | Nuevos agonistas ppar-alfa y ppar-gamma | |
MXPA04006571A (es) | Derivado de pirimidina biciclica fusionada. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |